Literature DB >> 11733155

Hepatocellular carcinoma after radiofrequency ablation therapy: dynamic CT evaluation of treatment.

M Tsuda1, K Majima, T Yamada, H Saitou, T Ishibashi, S Takahashi.   

Abstract

The aim of this study is to analyze the dynamic CT findings after radiofrequency (RF) ablation for hypervascular hepatocellular carcinoma (HCC). RF ablation was used for 22 tumors in 20 patients. Peripheral enhancement was noted in 89% of regions within 1 month in the arterial phase. In 1-3 months, peripheral enhancement remained at 56% and was reduced to 22% by 3-6 months. It is difficult to determine the therapeutic result within 3 months due to continued peripheral enhancement in the arterial phase.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11733155     DOI： 10.1016/s0899-7071(01)00333-3

Source DB:  PubMed          Journal:  Clin Imaging        ISSN： 0899-7071            Impact factor:   1.605


  5 in total

1.  Contrast-enhanced ultrasound (CEUS) follow-up after radiofrequency ablation or cryoablation of focal liver lesions: treated-area patterns and their changes over time.

Authors:  Aymeric Guibal; Caroline Bertin; Sophie Egels; Eric Savier; Philippe A Grenier; Olivier Lucidarme
Journal:  Eur Radiol       Date:  2012-11-09       Impact factor: 5.315

Review 2.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

3.  Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent.

Authors:  Yicheng Ni; Feng Chen; Stefaan Mulier; Xihe Sun; Jie Yu; Willy Landuyt; Guy Marchal; Alfons Verbruggen
Journal:  Eur Radiol       Date:  2006-01-21       Impact factor: 5.315

4.  Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT.

Authors:  S Tokunaga; M Koda; T Matono; T Sugihara; T Nagahara; M Ueki; Y Murawaki; S Kakite; E Yamashita
Journal:  Br J Radiol       Date:  2011-03-08       Impact factor: 3.039

5.  Dynamic evolutionary changes in blood flow measured by MDCT in a hepatic VX2 tumor implant over an extended 28-day growth period: time-density curve analysis.

Authors:  Hanping Wu; Agata A Exner; Hong Shi; Joshua Bear; John R Haaga
Journal:  Acad Radiol       Date:  2009-12       Impact factor: 3.173
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.